Richard A Hubner
University of Manchester
What is this?
Publications 201
#1Zev A. Wainberg (UCLA: University of California, Los Angeles)H-Index: 32
#2Tanios Bekaii-Saab (Mayo Clinic)H-Index: 39
Last. Bin Zhang (Ipsen)H-Index: 1
view all 11 authors...
#1Mairéad G McNamara (University of Manchester)H-Index: 19
#2Melissa FrizzieroH-Index: 8
Last. Eitan Amir (Princess Margaret Cancer Centre)H-Index: 37
view all 7 authors...
Background:There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating seco...
BACKGROUND: The prognostic significance of lymph nodes (LNs) metastases and the optimum number of LN yield in gastroenteropancreatic neuroendocrine tumours (GEP NETs) undergoing curative resection is still debatable. Many studies have demonstrated that cure rate for patients with GEP NETs can be improved by the resection of the primary tumour and regional lymphadenectomy. AIM: To evaluate the effect of lymph node (LN) status and yield on relapse-free survival (RFS) and overall survival (OS) in p...
Hepatocellular carcinoma (HCC) is a frequent and increasing cause of cancer-related deaths worldwide. Reversing this trend is complicated by the varied aetiological factors leading to liver cirrhosis resulting in molecular genetic and clinical heterogeneity, combined with frequent presentation at advanced stage. Large-scale genomic studies have identified alterations in key signalling pathways for HCC development and progression, but these findings have not yet directly influenced patient manage...
#1G. Andrew D. Briggs (Lond: University of London)H-Index: 91
#1Andrew Briggs (Lond: University of London)
Last. Gabriel TremblayH-Index: 4
view all 9 authors...
BACKGROUND: In the Phase 3 REFLECT trial in patients with unresectable hepatocellular carcinoma (uHCC), the multitargeted tyrosine kinase inhibitor, lenvatinib, was noninferior to sorafenib in the primary outcome of overall survival. Post-hoc review revealed imbalances in prognostic variables between treatment arms. Here, we re-analyse overall survival data from REFLECT to adjust for the imbalance in covariates. METHODS: Univariable and multivariable adjustments were undertaken for a candidate s...
#2Mairéad G McNamara (University of Manchester)H-Index: 19
Last. Richard A HubnerH-Index: 21
view all 6 authors...
Abstract Advanced hepatocellular cancer (HCC) is the fourth leading cause of cancer-related death globally and is most common in elderly patients with a peak incidence in the UK at ages 85–89 years. In addition to the well-established risk factors of alcohol and viral hepatitis B and C, rising obesity and associated non-alcoholic fatty liver disease is projected to contribute to increased incidence of advanced HCC in elderly patients. The management of advanced HCC is changing rapidly; for over ...
#2Jorge BarriusoH-Index: 22
Last. Angela LamarcaH-Index: 12
view all 7 authors...
BACKGROUND: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs. METHODS: Eligible studies (identified using MEDLINE-PubMed) were those reporting data on NEN patients who had undergone any type...
#1Angela Lamarca (University of Manchester)H-Index: 12
#2Julien EdelineH-Index: 23
Last. Juan W. Valle (University of Manchester)H-Index: 43
view all 8 authors...
Abstract Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ∼20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60-70% of patients expected to have disease recurrence. Most relapses occur in the form of distant...
2 CitationsSource
#1Harry H. Yoon (Mayo Clinic)H-Index: 20
Last. Jianming XuH-Index: 78
view all 8 authors...
TPS462Background: Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer, particularly in Asian countries. Inhibition of the PD-1/PD-L1 axis has demo...